| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Mar―08 |
Chrysin 7-O-β-D-glucuronide is not a potential inhibitor against SARS-CoV-2 main protease |
Rui Zhang, Jiahao Zhou, Haohao Yan, Xiaoping Liu, Yunyu Chen |
| 2 |
[GO] |
2024―Feb―24 |
Increase of multidrug-resistant bacteria after the COVID-19 pandemic in a major teaching Hospital in Sicily (2018-2021) |
Emanuele Amodio, Stefano Pizzo, Giuseppe Vella, Valerio De Francisci, Salvatore Antonino Distefano, Eliana Giambelluca, Domenico Graceffa, Maria Gabriella Verso, Ettore Piro, Mario Giuffrè, Giovanni Maurizio Giammanco, Giuseppe Calamusa |
| 3 |
[GO] |
2024―Feb―12 |
Effectiveness of oseltamivir in reducing COVID-19 related in-hospital deaths: a pharmacoepidemiologic study |
Char Leung, Li Su, Lucy Taylor, Eduardo Araújo Oliveira, Ana Cristina Simões e Silva |
| 4 |
[GO] |
2024―Jan―23 |
Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalized children aged 1-3 years with SARS-CoV-2 Omicron infection |
Carlos K.H. WONG, Kristy T.K. LAU, Ivan C.H. AU, Eric H.Y. LAU, Benjamin J. COWLING |
| 5 |
[GO] |
2024―Jan―21 |
Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy versus monotherapy for high-risk immunocompromised patients with mild to moderate SARS-CoV2 infection during Omicron era. A prospective cohort study |
J. Calderón-Parra, Andrea Gutiérrez-Villanueva, Gerard Ronda-Roca, Maria Luisa Martín Jimenez, Helena de la Torre, María Ródenas-Baquero, María Paniura-Pinedo, Carla Lozano-Llano, Ilduara Pintos-Pascual, Fernández-Cruz Ana, Antonio Ramos-Martínez, Elena Muñez-Rubio |
| 6 |
[GO] |
2024―Jan―19 |
Association between high dose of molnupiravir and COVID-19 mortality rate |
Li-Chen Chang, I-Wen Chen, Kuo-Chuan Hung |
| 7 |
[GO] |
2024―Jan―18 |
In reply to comment on “Association between high dose of molnupiravir and COVID-19 mortality rate” |
Zhaoyan Chen, Fangyuan Tian |
| 8 |
[GO] |
2024―Jan―18 |
Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis |
Bei Zheng, Qinqin Zhao, Wenjuan Yang, Pinpin Feng, Chuanwei Xin, Yin Ying, Bo Yang, Bing Han, Jun Zhu, Meiling Zhang, Gonghua Li |
| 9 |
[GO] |
2023―Dec―31 |
Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice |
Kwang-Soo Shin, Byung-Seok Kim, Soojeong Chang, In Kyung Jung, Hyemin Park, Seowoo Park, Jieun Shin, Jong Heon Kim, Sang-Jun Han, Bongju Park, Jae-Ouk Kim, Jung-Ah Lee, Tae-Young Lee, Chang-Yuil Kang |
| 10 |
[GO] |
2023―Dec―14 |
Comment on ‘Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19’ |
Ying-Li Lin, Chao-Hung Yu, James Cheng-Chung Wei |
| 11 |
[GO] |
2023―Nov―18 |
Chrysin 7-O-β-D-glucuronide, a dual inhibitor of SARS-CoV-2 3CLpro and PLpro, for the prevention and treatment of COVID-19 |
Yang Yi, Rong Yu, Heng Xue, Zhengtong Jin, Meng Zhang, Yang-oujie Bao, Zilong Wang, Hongping Wei, Xue Qiao, Hang Yang |
| 12 |
[GO] |
2023―Oct―28 |
Impact of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia |
Yong-Cheng Yii, Hong-Mo Shih, Chieh-Lung Chen, Zi-Lun Lai, Yu-Lung Hsu, Chia-Hong Lai, Po-Ren Hsueh, Der-Yang Cho |
| 13 |
[GO] |
2023―Sep―27 |
The association between nirmatrelvir plus ritonavir and the outcomes of nonhospitalized obese patients with COVID-19 |
Jheng-Yan Wu, Mei-Yuan Liu, Ting-Hui Liu, Min-Hsiang Chuang, Wan-Hsuan Hsu, Po-Yu Huang, Ya-Wen Tsai, Chih-Cheng Lai |
| 14 |
[GO] |
2023―Aug―13 |
MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY |
Jon SALMANTON-GARCÍA, Francesco MARCHESI, Philipp KOEHLER, Barbora WEINBERGEROVÁ, Natasa ČOLOVIĆ, Iker FALCES-ROMERO, Caterina BUQUICCHIO, Francesca FARINA, Jens VAN PRAET, Monika M. BIERNAT, Federico ITRI, Lucia PREZIOSO, Carlo TASCINI, Antonio VENA, Alessandra ROMANO, Mario DELIA, Julio DÁVILA-VALLS, Sonia MARTÍN-PÉREZ, Esperanza LAVILLA-RUBIRA, Tatjana ADŽIĆ-VUKIČEVIĆ, Daniel GARCÍA-BORDALLO, Alberto LÓPEZ-GARCÍA, Mariana CRISCUOLO, Verena PETZER, Nicola S. FRACCHIOLLA, Ildefonso ESPIGADO, Uluhan SILI, Stef MEERS, Nurettin ERBEN, Chiara CATTANEO, Athanasios TRAGIANNIDIS, Eleni GAVRIILAKI, Martin SCHÖNLEIN, Mirjana MITROVIC, Nikola PANTIC, Maria MERELLI, Jorge LABRADOR, José-Ángel HERNÁNDEZ-RIVAS, Andreas GLENTHØJ, Guillemette FOUQUET, Maria Ilaria DEL PRINCIPE, Michelina DARGENIO, María CALBACHO, Caroline BESSON, Milena KOHN, Stefanie GRÄFE, Ditte Stampe HERSBY, Elena ARELLANO, Gökçe MelisÇOLAK, Dominik WOLF, Monia MARCHETTI, Anna NORDLANDER, Ola BLENNOW, Raul CORDOBA, Bojana MIŠKOVIĆ, Miloš MLADENOVIĆ, Martina BAVASTRO, Alessandro LIMONGELLI, Laman RAHIMLI, Livio PAGANO, Oliver A. CORNELY |
| 15 |
[GO] |
2023―Aug―06 |
SARS-CoV-2 antibody response in SARS survivors with and without the COVID-19 vaccine |
Chang-sheng Xia, Minghua Zhan, Yudong Liu, Zhi-hong Yue, Ying Song, Feifei Zhang, Hui Wang |
| 16 |
[GO] |
2023―Jul―11 |
Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19 |
Mary E. Palmer, Rachel M. Belcher, Anastasia Engeleit, Eric Wenzler, Zackery P. Bulman, Scott T. Benken |
| 17 |
[GO] |
2023―Jul―08 |
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicenter randomized controlled clinical trial |
Shu Okugawa, Mahoko Ikeda, Kosuke Kashiwabara, Takashi Moritoyo, Takao Kohsaka, Toshio Shimizu, Hideharu Hagiya, Kou Hasegawa, Fumio Otsuka, Ayumi Miwa, Nobuhito Kisimoto, Ayako Mizoguchi, Akira Imamura, Kazuhiko Ikeuchi, Takeya Tsutsumi, Daisuke Jubishi, Hideki Hashimoto, Koh Okamoto, Sohei Harada, Jun-ichiro Inoue, Yasuyuki Seto, Kyoji Moriya |
| 18 |
[GO] |
2023―Jun―18 |
Exploration of the optimal GS-441524 trough concentration for treating COVID-19 |
Yuki Nakano, Yoko Inokuchi, Tadashi Hayama, Toshinori Hirai, Mamoru Nishiyama, Yoshiko Sueyasu, Kenjo Yokoo |
| 19 |
[GO] |
2023―Jun―18 |
Effective inhibition of HCoV-OC43 and SARS-CoV-2 by phytochemicals in vitro and in vivo. |
Durbadal Ojha, Forrest Jessop, Catharine M. Bosio, Karin E Peterson |
| 20 |
[GO] |
2023―May―26 |
Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Fangyuan Tian, Qiyi Feng, Zhaoyan Chen |
| 21 |
[GO] |
2023―May―13 |
The battle against fungi- lessons in antifungal stewardship from COVID-19 times: a consensus statement on behalf of the International Society of Antimicrobial Chemotherapy, Alliance for the Prudent Use of Antibiotics, European Society of Clinical Microbiology and Infectious Diseases Study Group for Antimicrobial Stewardship, and European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group |
Souha S. Kanj, Sara F. Haddad, Jacques F. Meis, Paul E. Verweij, Andreas Voss, Riina Rautemaa-Richardson, Gabriel Levy-Hara, Anuradha Chowdhary, Abdul Ghafur, Roger Brüggemann, Abhijit M. Bal, Jeroen Schouten |
| 22 |
[GO] |
2023―Apr―30 |
Clinical effectiveness of molnupiravir in COVID-19 patients undergoing hemodialysis |
Yi-Chin Chang, Yi-Chun Chen, Chiang-Chi Huang, Chung-Ming Fu, Yueh-Ting Lee, Po-Jung Wu, Wen-Chin Lee, Chien-Te Lee, Shang-Chih Liao, Kai-Fan Tsai |
| 23 |
[GO] |
2023―Apr―22 |
Efficacy of cefiderocol- versus colistin-containing regimen for treatment of bacteremic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in COVID-19 patients |
Alessandro Russo, Andrea Bruni, Sara Gullì, Cristian Borrazzo, Angela Quirino, Rosaria Lionello, Francesca Serapide, Eugenio Garofalo, Riccardo Serraino, Francesco Romeo, Nadia Marascio, Giovanni Matera, Federico Longhini, Enrico Maria Trecarichi, Carlo Torti |
| 24 |
[GO] |
2023―Jan―02 |
NIRMATRELVIR AND COVID-19DEVELOPMENT, PHARMACOKINETICS, CLINICAL EFFICACY, RESISTANCE, RELAPSES, AND PHARMACOECONOMICS. |
Daniele Focosi, Scott McConnell, Shmuel Shoham, Arturo Casadevall, Fabrizio Maggi, Guido Antonellli |
| 25 |
[GO] |
2022―May―17 |
Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics |
Rajat Desikan, Pranesh Padmanabhan, Andrzej M. Kierzek, Piet H. van der Graaf |
| 26 |
[GO] |
2022―Feb―06 |
The effect of sofosbuvir-based treatment on the clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Chi-Kuei Hsu, Ching-Yi Chen, Wang-Chun Chen, Chih-Cheng Lai, Shun-Hsing Hung, Wei-Ting Lin |
| 27 |
[GO] |
2022―Jan―31 |
Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2 |
Laura N Jeffreys, Shaun H Pennington, Jack Duggan, Claire H Caygill, Rose C Lopeman, Alastair F Breen, Jessica B Jinks, Alison Ardrey, Samantha Donnellan, Edward I Patterson, Grant L Hughes, David W Hong, Paul M O'Neill, Ghaith Aljayyoussi, Andrew Owen, Stephen A Ward, Giancarlo A Biagini |
| 28 |
[GO] |
2022―Jan―06 |
High dose ivermectin for the early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof of concept clinical trial |
Dora Buonfrate, Fabio Chesini, Davide Martini, Maria Carla Roncaglioni, Maria Luisa Ojeda Fernandez, Maria Francesca Alvisi, Irene De Simone, Eliana Rulli, Alessandro Nobili, Giacomo Casalini, Spinello Antinori, Marco Gobbi, Caterina Campoli, Michela Deiana, Elena Pomari, Gianluigi Lunardi, Roberto Tessari, Zeno Bisoffi |
| 29 |
[GO] |
2021―Dec―17 |
Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice |
Elishiba Muturi, Wei Hong, Junhua Li, Wan Yang, Jin He, Hongping Wei, Hang Yang |
| 30 |
[GO] |
2021―Oct―25 |
Evaluation of early antibiotic use in non-severe COVID-19 patients without bacterial infection |
Xiaoxv Yin, Xing Xu, Hui Li, Nan Jiang, Jing Wang, Zuxun Lu, Nian Xiong, Yanhong Gong |
| 31 |
[GO] |
2021―Oct―14 |
Change in Antimicrobial Use during COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study |
Hana R. Winders, Pamela Bailey, Joseph Kohn, Carmen M. Faulkner-Fennell, Sara Utley, Evan Lantz, Lloyd Sarbacker, Julie Ann Justo, P. Brandon Bookstaver, Sharon Weissman, Hannah Ruegner, Majdi N. Al-Hasan |
| 32 |
[GO] |
2021―Sep―23 |
Assessment of the knowledge and applications of infection control in Ayurvedic health care staff working in COVID-19 intermediate centres, Sri Lanka |
D. Wickramasinghe, PW Vidanage, DK Lokuhewagama, SAPDC Saranasinghe, SPKH Arachchige, BS Pathum |
| 33 |
[GO] |
2021―Sep―23 |
Identification of daclatasvir as a repurposed drug against Nsp15 of SASR-CoV2 (COVID-19) by using in silico approaches |
Prakash Jha, Madhu Chopra |
| 34 |
[GO] |
2021―Sep―23 |
COVID-19 associated mucormycois - unprecedented experience from a developing country |
V. Shwetha, C. Sneha, R. Ambica, S. Deepa, A. Aashish, P. Harshita, R. Shruthi, N. Shruti, P. Jyothirmai, G. Sunil, M. Silpa, B. Viswanatha, S. Nagarathna |
| 35 |
[GO] |
2021―Sep―23 |
The relationship between SARS-CoV-2 antibody titers and the severity of COVID-19 |
Joung Ha Park, Min Jae Cha, Hyewon Choi, Min-Chul Kim, Jin-Won Chung, Kyu-Sun Lee, Dae Gwin Jeong, Sun Woo Yoon, Seong-Ho Choi |
| 36 |
[GO] |
2021―Sep―23 |
Vaccine-associated disease enhancement: a case report of post-vaccination COVID-19 |
Rahajeng N. Tunjungputri, Erpryta Nurdia Tetrasiwi, Merlinda Veronica, Jacub Pandelaki, Fera Ibrahim, Erni Juwita Nelwan |
| 37 |
[GO] |
2021―Sep―23 |
Impact of COVID-19 pandemic on HIV care delivery and access in Asia |
Chien-Ching Hung, TinHung Wong, Shikha Singh, Yeni Kim, Jun Yong Choi |
| 38 |
[GO] |
2021―Sep―23 |
Therapeutics for COVID-19 |
Yaseen M. Arabi |
| 39 |
[GO] |
2021―Sep―23 |
Long-term sequelae of COVID-19 |
Bin Cao |
| 40 |
[GO] |
2021―Sep―23 |
Secondary bacterial and fungal infections in COVID-19 patients |
Krithika Varshini M., Vithiya Ganesan, Jhansi Charles |
| 41 |
[GO] |
2021―Sep―23 |
Psychological effects of paramedics by experience of managing COVID-19 patients |
Bongyoung Kim, Soyoon Hwang, Hyun Wook Ryoo, Un Sun Chung, So Hee Lee, Ju-Yeon Lee, Ji-Yeon Shin, Sang-geun Bae, Ki Tae Kwon |
| 42 |
[GO] |
2021―Sep―23 |
The estimation of direct hospital costs and Intensive Care Units (ICU) admissions for COVID-19 patients and the assessment of the impact of remdesivir administration in the Saudi Arabian context |
Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Basem Alraddadi, Alaa Alali, Sam Kozma, Camille Harfouche, Tariq AlMusawi |
| 43 |
[GO] |
2021―Sep―23 |
Use of personal protective equipment by healthcare workers exposed to COVID-19 patients at a tertiary care hospital in a lower middle-income country |
T.P.W. Perera, D.M. Mendis, S.S. Manoj, G.K. Iresha, P.C.L.S. Buddhadasa, H.C.L. Hansani, Kushlani Jayatilleke |
| 44 |
[GO] |
2021―Sep―23 |
Community acquired co-infection and trends in antimicrobial use among COVID-19 patients in a referral center in the Philippines |
Cybele Lara R. Abad, Joanne Carmela M. Sandejas, Jonnel B. Poblete, Anna Flor G. Malundo, Maria Sonia S. Salamat, Marissa M. Alejandria |
| 45 |
[GO] |
2021―Sep―23 |
Bacterial and fungal secondary infections in COVID-19 patients in a tertiary healthcare center in Malaysia |
Siti Roszilawati Ramli, Fashihah Sherina Abdul Hadi, Insyirah Husna Kamaradin, Norazah Ahmad |
| 46 |
[GO] |
2021―Sep―23 |
Hospitalization decision model for COVID-19 patients with comorbidities |
Irina Lizinfeld |
| 47 |
[GO] |
2021―Sep―23 |
Place of COVID-19 transmission in blood transmission: A case report |
Champika Gamlath, Darshana Wickramasinghe, Eshan Madusha |
| 48 |
[GO] |
2021―Sep―23 |
Low uptake of seasonal influenza and COVID-19 vaccine in nurses in Hong Kong |
C.P. Chan, N.S. Wong, S.S. Lee |
| 49 |
[GO] |
2021―Sep―23 |
Parenteral and oral anticoagulant treatment for hospitalized and post-discharge patients with COVID-19: A systematic review |
Rahajeng N. Tunjungputri, Erpryta N. Tetrasiwi, Tasykuru Rizqa, Nadia A. Mulansari, Kuntjoro Harimurti |
| 50 |
[GO] |
2021―Sep―23 |
Real-time PCR detects 4 rapid transmission variants of SARS-CoV-2 |
Van H. Pham, Chien D. Vo, Ha M. Nguyen, Binh T. Pham, Sa H. Le, Duy K. Trãn, Quoc V. Nguyen, Viet Q. Tran, Huong T. Pham, Son T. Pham, Nam H.D. Nguyen |
| 51 |
[GO] |
2021―Sep―23 |
Human airway epithelial Calu-3 cells as the potential platform to study the pathophysiology of SARS-CoV-2 isolated in Malaysia |
Siti Nur Zawani Rosli, Sitti Rahmawati Dimeng, Farah Shamsuddin, Mohammad Ridhuan Mohd Ali, Nur Afrina Muhamad Hendri, Hana Farizah Zamri, Jeyanthi Suppiah, Zarina Mohd Zawawi, Rozainanee Mohd Zain, Ravindran Thayan, Norazah Ahmad |
| 52 |
[GO] |
2021―Sep―23 |
Clinical and laboratory factors in predicting mortality among SARS-CoV-2 RNA positive patients from a tertiary care center in South Tamilnadu - A retrospective observational study |
Vithiya Ganesan, Raja Sundaramurthy, B Surya Kumar, T Rajendran, Jhansi Charles |
| 53 |
[GO] |
2021―Sep―23 |
Assessing risk factors for health care associated transmission of SARS-Cov-2 virus infection among health care personnel in a tertiary care hospital, Sri Lanka; a case-control study |
D.M. Mendis, T.P.W. Perera, S.S. Manoj, G.K. Iresha, P.C.L.S. Buddhadasa, H.C.L. Hansani, Kushlani Jayatilleke |
| 54 |
[GO] |
2021―Sep―23 |
Effect of Lonicera caerulea on cytokine production of alveolar macrophages by stimulation with SARS-CoV-2-related proteins |
Masaaki Minami, Mineo Nakamura |
| 55 |
[GO] |
2021―Sep―23 |
Host-pathogen interactional proteomic atlas of pandemic influenza A virus infection in primary human T cells |
Jiapei Yu, Hui Li, Bin Cao |
| 56 |
[GO] |
2021―Sep―23 |
Effect of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine |
Jinyoung Yang, Jae-Hoon Ko, Jin Yang Baek, Jinyeong Hong, Soyoung Ha, Beomki Lee, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Doo Ryeon Chung, Yae-Jean Kim, Eun-Suk Kang, Kyong Ran Peck |
| 57 |
[GO] |
2021―Sep―23 |
Antimicrobial stewardship during the COVID-19 pandemic |
Timothy M. Rawson |
| 58 |
[GO] |
2021―Sep―23 |
What we learned from COVID-19 vaccination |
Eui-Cheol Shin |
| 59 |
[GO] |
2021―Sep―23 |
Public health response to COVID-19: Global perspective |
Maria Van Kerkhove |
| 60 |
[GO] |
2021―Sep―23 |
COVID-19: Lessons from the Unfolding Pandemic |
Michael T. Osterholm |
| 61 |
[GO] |
2021―Sep―23 |
Public health response to COVID-19: National perspective from Taiwan |
Hsien-Ho Lin |
| 62 |
[GO] |
2021―Sep―23 |
Public health response to COVID-19: Regional perspective |
Sharon Salmon |
| 63 |
[GO] |
2021―Sep―23 |
Infection control for COVID-19: Theory and practice |
Kalisvar Marimuthu |
| 64 |
[GO] |
2021―Sep―23 |
Indoor transmission of SARS-CoV-2 |
Hua Qian |
| 65 |
[GO] |
2021―Sep―23 |
Vaccines against SARS-COV-2 |
Jerome H. Kim |
| 66 |
[GO] |
2021―Aug―25 |
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance |
Cristhieni Rodrigues, Rodrigo S Freitas-Santos, José Eduardo Levi, Andreza A Senerchia, Ana Tarina A Lopes, Sergio R Santos, Rinaldo F Siciliano, Lígia C Pierrotti |
| 67 |
[GO] |
2021―Apr―07 |
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomized control clinical trial |
Fahad Faqihi, Abdulrahman Alharthy, Salman Abdulaziz, Abdullah Balhamar, Awad Alomari, Zohair AlAseri, Hani Tamim, Saleh A. Alqahtani, Demetrios J Kutsogiannis, Peter G Brindley, Dimitrios Karakitsos, Ziad A Memish |
| 68 |
[GO] |
2021―Mar―20 |
Increased antimicrobial resistance during the COVID-19 pandemic |
Chih-Cheng Lai, Shey-Ying Chen, Wen-Chien Ko, Po-Ren Hsueh |
| 69 |
[GO] |
2021―Mar―18 |
Timing and dosage may be the key in the realization of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients |
Dr Alexis LACOUT, Dr VALERE LOUNNAS, Pr Christian PERRONNE |
| 70 |
[GO] |
2021―Mar―12 |
Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment |
Hervé Seligmann |
| 71 |
[GO] |
2021―Feb―16 |
Effect of hydroxychloroquine and azythromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann |
Philippe Gautret, Van Thuan Hoang, Philippe Colson, Didier Raoult |
| 72 |
[GO] |
2021―Jan―27 |
Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals |
R.J. Brüggemann, D.J.A.R. Moes, K.P. van Rhee, N.E. van 't Veer, B.C.P. Koch, M. van Rossum, A. Vermeulen Windsant - van den Tweel, M.H.E. Reijers, R.R.J. van Kimmenade, J.C. Rahamat-Langedoen, T.C.D. Rettig, R. van Raalte, J. van Paassen, F.N. Polderman, P.D. van der Linden, T. Frenzel, Q. de Mast, D.M. Burger, J. Schouten, F.L. van de Veerdonk, P. Pickkers, R. ter Heine |
| 73 |
[GO] |
2021―Jan―19 |
Azithromycin, treatment in COVID-19 |
Omar Belfaqeeh, Jigar Patel, Rajesh Naidu Janapala, Abdulla Alhashmi, Ali Pourmand |
| 74 |
[GO] |
2021―Jan―19 |
Reply to the letter to the editor “Azithromycin, treatment in COVID-19” |
Navid Manafi, Fereshteh Ghiasvand |
| 75 |
[GO] |
2021―Jan―04 |
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19 |
Philippe Gautret, Jean-Christophe Lagier, Stéphane Honoré, Van Thuan Hoang, Didier Raoult |
| 76 |
[GO] |
2021―Jan―04 |
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19 |
Philippe Colson, Bernard La Scola, Jean-Christophe Lagier, Philippe Gautret, Didier Raoult |
| 77 |
[GO] |
2021―Jan―04 |
Advanced statistical methods and designs for clinical trials for COVID-19 |
Guogen Shan, Weizhen Wang |
| 78 |
[GO] |
2021―Jan―04 |
Response to advances statistical methods and designs for clinical trials for COVID-19 |
Philippe Gautret, Van Thuan Hoang, Jean-Christophe Lagier, Didier Raoult |
| 79 |
[GO] |
2021―Jan―04 |
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature |
Jason D. Goldman, George Diaz, Walter J. Urba |
| 80 |
[GO] |
2021―Jan―04 |
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. |
Philippe Gautret, Van Thuan Hoang, Stéphane Honoré, Yanis Roussel, Matthieu Million, Jean-Christophe Lagier, Didier Raoult |
| 81 |
[GO] |
2021―Jan―04 |
Can we use hydroxychloroquine to treat COVID-19 now? |
Jun Chen, Danping Liu, Lin Yin, Lijun Zhang, Hongzhou Lu |
| 82 |
[GO] |
2021―Jan―04 |
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients |
Philippe Gautret, Stéphane Honoré, Jean-Christophe Lagier, Didier Raoult |
| 83 |
[GO] |
2021―Jan―04 |
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. |
Matthieu Million, Yanis Roussel, Philippe Gautret, Didier Raoult |
| 84 |
[GO] |
2021―Jan―04 |
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
Philippe Gautret, Van Thuan Hoang, Jean-Christophe Lagier, Didier Raoult |
| 85 |
[GO] |
2021―Jan―04 |
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial |
Luis Gabriel Parra-Lara, Juan José Martinez-Arboleda, Daniel Francisco Isaza-Pierotti, Fernando Rosso |
| 86 |
[GO] |
2021―Jan―04 |
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial |
Marcelo Rodrigues dos Santos |
| 87 |
[GO] |
2021―Jan―04 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited |
Philippe Gautret, Jean-Christophe Lagier, Stéphane Honoré, Van Thuan Hoang, Philippe Colson, Didier Raoult |
| 88 |
[GO] |
2021―Jan―04 |
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes |
Philippe Gautret, Van Thuan Hoang, Jean-Christophe Lagier, Didier Raoult |
| 89 |
[GO] |
2021―Jan―04 |
Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
Carlos Gustavo Wambier |
| 90 |
[GO] |
2021―Jan―04 |
Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
Mohamed O Saad |
| 91 |
[GO] |
2021―Jan―04 |
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load |
Tuan V. Nguyen |
| 92 |
[GO] |
2021―Jan―04 |
Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load. |
Philippe Gautret, Van Thuan Hoang, Hervé Chaudet, Jean-Christophe Lagier, Didier Raoult |
| 93 |
[GO] |
2021―Jan―02 |
Passive immunization and its rebirth in the era of the COVID-19 pandemic |
Charles S. Pavia, Gary P. Wormser |
| 94 |
[GO] |
2020―Dec―30 |
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine |
Marion Plaze, David Attali, Matthieu Prot, Anne-Cécile Petit, Michael Blatzer, Fabien Vinckier, Laurine Levillayer, Jeanne Chiaravalli, Florent Perin-Dureau, Arnaud Cachia, Gérard Friedlander, Fabrice Chrétien, Etienne Simon-Loriere, Raphaël Gaillard |
| 95 |
[GO] |
2020―Dec―25 |
Plasma exchange in the treatment of complex COVID-19 related critical illness: controversies and perspectives |
Ziad A. Memish, Fahad Faqihi, Abdulrahman Alharthy, Saleh A Alqahtani, Dimitrios Karakitsos |
| 96 |
[GO] |
2020―Dec―23 |
Different mutations in SARS-CoV-2 associate with severe and mild outcome |
Ádám Nagy, Sándor Pongor, Balázs Győrffy |
| 97 |
[GO] |
2020―Dec―17 |
Early Clinical Outcomes with Tocilizumab for Severe Covid-19: A Two-Center Retrospective Study |
Steven M. Smoke, Karan Raja, Patrick Hilden, Nicole M. Daniel |
| 98 |
[GO] |
2020―Dec―13 |
Reply to the letter to the editor “Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.” |
Nicolas Dauby, Lucy Catteau, Joris Hautekiet, Marion Montourcy, Emmanuel Bottieau, Els Goetghebeur, Dominique Van Beckhoven |
| 99 |
[GO] |
2020―Dec―09 |
Vertical transmission and kidney damage in newborns from coronavirus disease 2019 infection pregnant mother |
Zheng He, Yinian Fang, Qin Zuo, Xiaoxing Huang, Yongfang Lei, Xiuhua Ren, Dong Liu |
| 100 |
[GO] |
2020―Nov―28 |
Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19 |
S. RUIZ, D. CONCORDET, T. LANOT, B. GEORGES, P. GOUDY, S. BAKLOUTI, C. MANE, E. LOSHA, H. VINOUR, D. ROUSSET, M. LAVIT, V. MINVILLE, J-M CONIL, P. GANDIA |
| 101 |
[GO] |
2020―Nov―28 |
COVID-19 in hospitalized patients in Spain: a cohort study in Madrid |
Carmen Rodriguez-Gonzalez, Esther Chamorro-de-Vega, Maricela Valerio, Miguel Angel Amor-Garcia, Francisco Tejerina, Milagros Sancho-Gonzalez, Alvaro Narrillos-Moraza, Alvaro Gimenez-Manzorro, Silvia Manrique-Rodriguez, Marina Machado, Maria Olmedo, Vicente Escudero-Vilaplana, Cristina Villanueva-Bueno, Beatriz Torroba-Sanz, Alejandra Melgarejo-Ortuño, Juan Vicente-Valor, Ana Herranz, Emilio Bouza, Patricia Muñoz, Maria Sanjurjo |
| 102 |
[GO] |
2020―Nov―28 |
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin |
Martin D. Hellwig, Anabela Maia |
| 103 |
[GO] |
2020―Nov―28 |
Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality |
Nicolas De Schryver, Nicolas Serck, Marco Vinetti, Ludovic Gérard |
| 104 |
[GO] |
2020―Nov―27 |
Klebsiella pneumoniae infections in COVID-19 patients: a two-month retrospective analysis in an Italian hospital |
Gabriele Arcari, Giammarco Raponi, Federica Sacco, Giulia Bibbolino, Federica Maria Di Lella, Francesco Alessandri, Monica Coletti, Maria Trancassini, Alberto Deales, Francesco Pugliese, Guido Antonelli, Alessandra Carattoli |
| 105 |
[GO] |
2020―Nov―13 |
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020 |
Tran Duc Anh Ly, Didier Zanini, Vincent Laforge, Sylvie Arlotto, Stephanie Gentile, Helene Mendizabal, Michael Finaud, David Morel, Olivier Quenette, Priscilla Malfuson-Clot-Faybesse, Alain Midejean, Phuc Le-Dinh, Gérard Daher, Berengere Labarriere, Anne-Marie Morel-Roux, Alain Coquet, Patrick Augier, Philippe Parola, Eric Chabriere, Didier Raoult, Philippe Gautret |
| 106 |
[GO] |
2020―Nov―12 |
Randomized Controlled Trials for COVID-19: Evaluation of Optimal Randomization Methodologies - Need for the Data Validation of the Completed Trials, and to Improve the Ongoing and Future Randomized Trial Designs |
Venkata R. Emani, Sanjeev Goswami, Dheeraj Nandanoor, Shaila R. Emani, Nidhi K. Reddy, Raghunath Reddy |
| 107 |
[GO] |
2020―Nov―06 |
LPD-12, a Promising Lipopeptide to Control COVID-19 |
Trinath Chowdhury, Piyush Baindara, Santi M. Mandal |
| 108 |
[GO] |
2020―Nov―06 |
Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study |
Dr. Deba Prasad Dhibar, Dr. Navneet Arora, Dr. Arpit Kakkar, Dr. Neeraj Singla, Dr. Ritin Mohindra, Dr. Vikas Suri, Dr. Ashish Bhalla, Dr. Navneet Sharma, Dr. Mini P Singh, Dr. Ajay Prakash, Dr. Lakshmi PVM, Dr. Bikash Medhi |
| 109 |
[GO] |
2020―Nov―02 |
Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial |
Guoming Li, Mei Yuan, Haihong Li, Changsheng Deng, Qi Wang, Yexiao Tang, Hongying Zhang, Weisheng Yu, Qin Xu, Yuanyuan Zou, Yueming Yuan, Jiawen Guo, Chunming Jin, Xiangdong Guan, Fengjie Xie, Jianping Song |
| 110 |
[GO] |
2020―Oct―26 |
COVID-19 outpatients - early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study |
Roland Derwand, Martin Scholz, Vladimir Zelenko |
| 111 |
[GO] |
2020―Oct―24 |
Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: a Meta-analysis |
Teodoro J. Oscanoa, Xavier Vidal, Jørgen K. Kanters, Roman Romero-Ortuno |
| 112 |
[GO] |
2020―Oct―23 |
Therapeutic Modalities and Novel Approaches in Regenerative Medicine for COVID-19 |
Roya Ramezankhani, Roya Solhi, Arash Memarnejadian, Fatemeharefeh Nami, Seyed MohammadReza Hashemian, Tine Tricot, Massoud Vosough, Catherine Verfaillie |
| 113 |
[GO] |
2020―Oct―16 |
Methylene blue inhibits the replication of SARS-Cov-2 in vitro |
Mathieu Gendrot, Julien Andreani, Isabelle Duflot, Manon Boxberger, Marion Le Bideau, Joel Mosnier, Priscilla Jardot, Isabelle Fonta, Clara Rolland, Hervé Bogreau, Sébastien Hutter, Bernard La Scola, Bruno Pradines |
| 114 |
[GO] |
2020―Oct―09 |
Projected supportive effects of Pycnogenol® in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection |
Franziska Weichmann, Peter Rohdewald |
| 115 |
[GO] |
2020―Sep―25 |
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients |
Priya Nori, Wendy Szymczak, Yoram Puius, Anjali Sharma, Kelsie Cowman, Philip Gialanella, Zachary Fleischner, Marilou Corpuz, Julian Torres-Isasiga, Rachel Bartash, Uriel Felsen, Victor Chen, Yi Guo |
| 116 |
[GO] |
2020―Sep―25 |
Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics |
Arafat Rahman Oany, Mamun Mia, Tahmina Pervin, Md. Junaid, S.M. Zahid Hosen, Mohammad Ali Moni |
| 117 |
[GO] |
2020―Aug―27 |
Antimicrobial stewardship program, a vital resource for hospitals during the global outbreak of Coronavirus Disease 2019 (COVID-19) |
Yixin Liew, Winnie Hui Ling Lee, Lunyi Tan, Andrea Lay Hoon Kwa, Siew Yee Thien, Benjamin Pei Zhi Cherng, Shimin Jasmine Chung |
| 118 |
[GO] |
2020―Aug―25 |
NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial |
Ehsan Sekhavati, Fatemeh Jafari, SeyedAhmad SeyedAlinaghi, Saeidreza Jamali Moghadam Siahkali, Sara Sadr, Mohammad Tabarestani, Mohammad Pirhayati, Abolfazl Zendehdel, Navid Manafi, Mahboubeh Hajiabdolbaghi, Zahra Ahmadinejad, Hamid Emadi Kouchak, Sirous Jafari, Hosein Khalili, Mohamadreza Salehi, Arash Seifi, Fereshteh Shahmari Golestan, Fereshteh Ghiasvand |
| 119 |
[GO] |
2020―Aug―24 |
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19 |
Sergio Padilla, Guillermo Telenti, Lucía Guillén, José Alberto García, Javier García-Abellán, Carolina Ding, Antonia Mora, Eduardo García-Pachón, Félix Gutiérrez, Mar Masiá |
| 120 |
[GO] |
2020―Aug―24 |
Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants |
Lucy Catteau, Nicolas Dauby, Marion Montourcy, Emmanuel Bottieau, Joris Hautekiet, Els Goetghebeur, Sabrina van Ierssel, Els Duysburgh, Herman Van Oyen, Chloé Wyndham-Thomas, Dominique Van Beckhoven |
| 121 |
[GO] |
2020―Aug―18 |
Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948] |
Lisheng Wang, Yiru Wang, Dawei Ye, Qingquan Liu |
| 122 |
[GO] |
2020―Aug―08 |
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results |
Alexandre Lopez, Gary Duclos, Bruno Pastene, Karine Bezulier, Romain Guilhaumou, Caroline Solas, Laurent Zieleskiewicz, Marc Leone |
| 123 |
[GO] |
2020―Aug―02 |
nImpact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time |
Benjamin Davido, Ghilas Boussaid, Isabelle Vaugier, Thibaud Lansaman, Frédérique Bouchand, Christine Lawrence, Jean-Claude Alvarez, Pierre Moine, Véronique Perronne, Frédéric Barbot, Azzam Saleh-Mghir, Christian Perronne, Djillali Annane, Pierre De Truchis |
| 124 |
[GO] |
2020―Jul―30 |
Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19 |
Emre Kara, Kutay Demirkan, Serhat Unal |
| 125 |
[GO] |
2020―Jul―30 |
Lactoferrin as potential preventative and treatment for COVID-19 |
Raymond Chang, Tzi Bun Ng, Wei-Zen Sun |
| 126 |
[GO] |
2020―Jul―30 |
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): A link between antiviral and anticancer mechanisms? |
Daniel F. Alonso, Hernán G. Farina |
| 127 |
[GO] |
2020―Jul―30 |
In silico Study of Azithromycin, Chloroquine and Hydroxychloroquine and their Potential Mechanisms of Action against SARS-CoV-2 Infection |
Helyson Lucas Bezerra Braz, João Alison de Moraes Silveira, Aline Diogo Marinho, Maria Elisabete Amaral de Moraes, Manoel Odorico de Moraes Filho, Helena Serra Azul Monteiro, Roberta Jeane Bezerra Jorge |
| 128 |
[GO] |
2020―Jul―23 |
Diagnostic performance of initial blood urea nitrogen combined with D-Dimer levels for predicting in-hospital mortality in COVID-19 patients |
Anying Cheng, Liu Hu, Yiru Wang, Luyan Huang, Lingxi Zhao, Congcong Zhang, Xiyue Liu, Ranran Xu, Feng Liu, Jinping Li, Dawei Ye, Tao Wang, Yongman Lv, Qingquan Liu |
| 129 |
[GO] |
2020―Jul―23 |
Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study |
Tong Song, Su Yuan, Yu Yuan, Wu Chuangyan, Chen Jiuling, Wang Sihua, Jiang Jinjun |
| 130 |
[GO] |
2020―Jul―23 |
Tocilizumab for severe COVID-19: a systematic review and meta-analysis |
Shao-Huan Lan, Chih-Cheng Lai, Hui-Ting Huang, Shen-Peng Chang, Li-Chin Lu, Po-Ren Hsueh |
| 131 |
[GO] |
2020―Jul―17 |
Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal. |
Mohammad Sultan Khuroo, Ahmad A Sofi, Mohammad Khuroo |
| 132 |
[GO] |
2020―Jul―16 |
No evidence of SARS-CoV-2 circulation before the identification of the first Swiss SARS-CoV-2 case. |
Loic Lhopitallier, Thomas Brahier, Onya Opota, Andreas Kronenberg, Yolanda Mueller, Olivier Hügli, Katia Jaton, Noémie Boillat-Blanco |
| 133 |
[GO] |
2020―Jul―13 |
Publishing in face of the COVID-19 pandemic |
Andreas Voss, Geoffrey Coombs, Serhat Unal, Raphael Saginur, Po-Ren Hsueh |
| 134 |
[GO] |
2020―Jul―13 |
Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949 |
Frits R. Rosendaal |
| 135 |
[GO] |
2020―Jul―13 |
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks? |
Julian D Machiels, Chantal P Bleeker-Rovers, Rob ter Heine, Janette Rahamat-Langendoen, Quirijn de Mast, Jaap ten Oever, Teun Bousema, Reinout van Crevel, Heiman FL Wertheim |
| 136 |
[GO] |
2020―Jul―10 |
Adaptation of Russian population to SARS-CoV-2: Asymptomatic course, comorbidities, mortality, and other respiratory viruses - A reply to Fear versus Data |
Konstantin S. Sharov |
| 137 |
[GO] |
2020―Jul―04 |
Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study |
Firouzé BANI-SADR, Maxime HENTZIEN, Madeline PASCARD, Yohan N'GUYEN, Amélie SERVETTAZ, Laurent ANDREOLETTI, Lukshe KANAGARATNAM, Damien JOLLY |
| 138 |
[GO] |
2020―Jul―04 |
COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus |
Yang Song, Min Zhang, Ling Yin, Kunkun Wang, Yiyi Zhou, Mi Zhou, Yun Lu |
| 139 |
[GO] |
2020―Jul―04 |
A pharmacological perspective of Chloroquine in SARS-CoV-2 infection |
Teodoro J. Oscanoa, Roman Romero-Ortuno, Alfonso Carvajal, Andrea Savarino |
| 140 |
[GO] |
2020―Jul―03 |
Letter to the Editor Regarding the recent contribution by Roussel et al. (SARS-CoV-2: Fear Versus Data) |
Axel Mosig |
| 141 |
[GO] |
2020―Jun―13 |
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
Sun In Hong, Byung-Han Ryu, Yong Pil Chong, Seungjun Lee, Sunjoo Kim, Ho Cheol Kim, Kyung-Wook Hong, In-Gyu Bae, Oh-Hyun Cho |
| 142 |
[GO] |
2020―Jun―11 |
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors |
Jun He, Lijun Hu, Xiaojun Huang, Chenran Wang, Zhimin Zhang, Ying Wang, Dongmei Zhang, Wencai Ye |
| 143 |
[GO] |
2020―Jun―10 |
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology |
Arianna Pani, Marinella Lauriola, Alessandra Romandini, Francesco Scaglione |
| 144 |
[GO] |
2020―Jun―10 |
Procalcitonin levels in COVID-19 patients |
Rui Hu, Chaofei Han, Shiyao Pei, Mingzhu Yin, Xiang Chen |
| 145 |
[GO] |
2020―Jun―10 |
Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies |
Atul Sharma, Swapnil Tiwari, Manas Kanti Deb, Jean Louis MARTY |
| 146 |
[GO] |
2020―Jun―06 |
Widely available lysosome targeting agents should be considered as a potential therapy for COVID-19 |
J. Homolak, I. Kodvanj |
| 147 |
[GO] |
2020―Jun―02 |
Tocilizumab administration in a refractory case of COVID-19 |
Farzaneh Dastan, Seyed Alireza Nadji, Ali Saffaei, Payam Tabarsi |
| 148 |
[GO] |
2020―May―23 |
IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS |
Giancarlo Ceccarelli, Francesco Alessandri, Gabriella d'Ettorre, Cristian Borrazzo, Ornella Spagnolello, Alessandra Oliva, Franco Ruberto, Claudio M. Mastroianni, Francesco Pugliese, Mario Venditti |
| 149 |
[GO] |
2020―May―22 |
Extra-respiratory manifestations of COVID-19 |
Chih-Cheng Lai, Wen-Chien Ko, Ping-Ing Lee, Shio-Shin Jean, Po-Ren Hsueh |
| 150 |
[GO] |
2020―May―22 |
Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports |
Valeria Gaspari, Corrado Zengarini, Sonia Greco, Valeria Vangeli, Antonio Mastroianni |
| 151 |
[GO] |
2020―May―22 |
A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic |
Satyajit Tripathy, Barsha Dassarma, Somenath Roy, Hlupheka Chabalala, Motlalepula Gilbert Matsabisa |
| 152 |
[GO] |
2020―May―13 |
nSynergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal |
Jacques Fantini, Henri Chahinian, Nouara Yahi |
| 153 |
[GO] |
2020―May―11 |
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. |
Ciccullo A., Borghetti A., Zileri Dal Verme L., Tosoni A., Lombardi F., Garcovich M., Biscetti F., Montalto M., Cauda R., Di Giambenedetto S. |
| 154 |
[GO] |
2020―May―08 |
Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking |
Ran Yu, Liang Chen, Rong Lan, Rong Shen, Peng Li |
| 155 |
[GO] |
2020―May―07 |
Tocilizumab in COVID-19: beware of risk of intestinal perforation |
Jens Vikse, Brandon Michael Henry |
| 156 |
[GO] |
2020―May―03 |
SARS-CoV-2 was already spreading in France in late December 2019 |
A. Deslandes, V. Berti, Y. Tandjaoui-Lambotte, Chakib Alloui, E. Carbonnelle, J.R. Zahar, S. Brichler, Yves Cohen |
| 157 |
[GO] |
2020―Apr―30 |
May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients? |
Emre Kara, Ahmet Cagkan Inkaya, Kutay Demirkan |
| 158 |
[GO] |
2020―Apr―29 |
Global coronavirus disease 2019: what has daily cumulative index taught us? |
Chih-Cheng Lai, Cheng-Yi Wang, Ya-Hui Wang, Po-Ren Hsueh |
| 159 |
[GO] |
2020―Apr―28 |
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ? |
Naveen Vankadari |
| 160 |
[GO] |
2020―Apr―24 |
Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 |
PanDong LuoLiu, Juan Li |
| 161 |
[GO] |
2020―Apr―17 |
Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals? |
Sun Hee Lee, Hyunjin Son, Kyong Ran Peck |
| 162 |
[GO] |
2020―Apr―16 |
Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies |
Ming Zhao |
| 163 |
[GO] |
2020―Apr―14 |
Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection |
Hua Shi, Chaomin Zhou, Pinghong He, Sheng Huang, Youjun Duan, Xuesheng Wang, Kexiong Lin, Chao Zhou, Xiangyan Zhang, Yan Zha |
| 164 |
[GO] |
2020―Apr―12 |
Chloroquine as prophylactic agent against COVID-19? |
Mathieu Gendrot, Emilie Javelle, Erwan Le Dault, Axelle Clerc, Hélène Savini, Bruno Pradines |
| 165 |
[GO] |
2020―Apr―10 |
Drug repositioning an alternative for the treatment of coronavirus COVID-19 |
Marissa B. Serafin, Angelita Bottega, Vitória S. Foletto, Taciéli F. da Rosa, Andreas Hörner, Rosmari Hörner |
| 166 |
[GO] |
2020―Apr―10 |
Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections |
Hanan Polansky, Gillad Lori |
| 167 |
[GO] |
2020―Apr―04 |
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: Prevention and Therapeutic Strategies |
Jaffar A. Al-Tawfiq, Ziad A. Memish |
| 168 |
[GO] |
2020―Apr―04 |
Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage |
Mark Olsen, Sarah Elizabeth Cook, Vanthida Huang, Niels Pedersen, Brian G. Murphy |
| 169 |
[GO] |
2020―Apr―03 |
Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection |
Jacques Fantini, Coralie Di Scala, Henri Chahinian, Nouara Yahi |
| 170 |
[GO] |
2020―Mar―29 |
Coronavirus disease 2019 (COVID-19): current status and future perspective |
Heng Li, Shang-Ming Liu, Xiao-Hua Yu, Shi-Lin Tang, Chao-Ke Tang |
| 171 |
[GO] |
2020―Mar―29 |
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality |
Chi Zhang, Zhao Wu, Jia-Wen Li, Hong Zhao, Gui-Qiang Wang |
| 172 |
[GO] |
2020―Mar―29 |
Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment |
Shuntong Kang, Wenyao Peng, Yuhao Zhu, Shiyao Lu, Min Zhou, Wei Lin, Wenfang Wu, Shu Huang, Liping Jiang, Xuan Luo, Meichun Deng |
| 173 |
[GO] |
2020―Mar―28 |
The epidemiology, diagnosis and treatment of COVID-19 |
Pan Zhai, Yanbing Ding, Xia Wu, Junke Long, Yanjun Zhong, Yiming Li |
| 174 |
[GO] |
2020―Mar―28 |
Complex emergencies of COVID-19: management and experience in Zhuhai |
Hao Jin, Ligong Lu, Junwei Liu, Min Cui |
| 175 |
[GO] |
2020―Mar―20 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |
Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Morgane Mailhe, Barbara Doudier, Johan Courjon, Valérie Giordanengo, Vera Esteves Vieira, Hervé Tissot Dupont, Stéphane Honoré, Philippe Colson, Eric Chabrière, Bernard La Scola, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult |
| 176 |
[GO] |
2020―Mar―19 |
A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence |
Li-sheng Wang, Yi-ru Wang, Da-wei Ye, Qing-quan Liu |
| 177 |
[GO] |
2020―Mar―19 |
Global epidemiology of coronavirus disease 2019: disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status |
Chih-Cheng Lai, Cheng-Yi Wang, Ya-Hui Wang, Shun-Chung Hsueh, Wen-Chien Ko, Po-Ren Hsueh |
| 178 |
[GO] |
2020―Mar―19 |
SARS-CoV-2: fear versus data |
Yanis Roussel, Audrey Giraud-Gatineau, Marie-Thérèse Jimeno, Jean-Marc Rolain, Christine Zandotti, Philippe Colson, Didier Raoult |
| 179 |
[GO] |
2020―Mar―17 |
Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine |
Zahra Sahraei, Minoosh Shabani, Shervin Shokouhi, Ali Saffaei |
| 180 |
[GO] |
2020―Mar―13 |
Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? |
Sophie Alexandra Baron, Christian Devaux, Philippe Colson, Didier Raoult, Jean-Marc Rolain |
| 181 |
[GO] |
2020―Mar―12 |
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
Christian A. Devaux, Jean-Marc Rolain, Philippe Colson, Didier Raoult |
| 182 |
[GO] |
2020―Mar―07 |
VSI: COVID-19 Therapeutic |
Didier Raoult, Po-Ren Hsueh, Stefani Stefania, Jean-Marc Rolain |
| 183 |
[GO] |
2020―Mar―06 |
Arguments in favor of remdesivir for treating SARS-CoV-2 infections |
Wen-Chien Ko, Jean-Marc Rolain, Nan-Yao Lee, Po-Lin Chen, Ching-Tai Huang, Ping-Ing Lee, Po-Ren Hsueh |
| 184 |
[GO] |
2020―Mar―04 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 |
Philippe Colson, Jean-Marc Rolain, Jean-Christophe Lagier, Philippe Brouqui, Didier Raoult |
| 185 |
[GO] |
2020―Feb―17 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges |
Chih-Cheng Lai, Tzu-Ping Shih, Wen-Chien Ko, Hung-Jen Tang, Po-Ren Hsueh |
| 186 |
[GO] |
2020―Feb―15 |
Chloroquine for the 2019 novel coronavirus |
Philippe Colson, Jean-Marc Rolain, Didier Raoult |
|
